

January 11, 2017

To,
Dy. General Manager
Department of Corporate Services,
Bombay Stock Exchange Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,


Sub: Statement of Investor Complaints.

Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended December 31, 2016:

SNo	Particulars	Details
1	No. of Investor Complaints pending at the beginning of the quarter	0
2	No. of Investor Complaints received during the quarter	33
3	No. of Investor Complaints disposed of during the quarter	33
4	No. of Investor Complaints those remaining unresolved at the end of the quarter	0

Please take the same on records.

Yours Faithfully,
For Glenmark Pharmaceuticals Limited



Rajesh V. Desai
Executive Director

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com